Skip to main content
Top
Published in: Health and Quality of Life Outcomes 1/2017

Open Access 01-01-2017 | Research

Nutritional status and quality of life of cancer patients needing exclusive chemotherapy: a longitudinal study

Authors: Sebastien Salas, Sophie Mercier, Benjamin Moheng, Sandrine Olivet, Marie-Eve Garcia, Sophie Hamon, Camille Sibertin-Blanc, Florence Duffaud, Pascal Auquier, Karine Baumstarck

Published in: Health and Quality of Life Outcomes | Issue 1/2017

Login to get access

Abstract

Background

The aims of this study were to report nutritional status in a large panel of patients with cancer requiring exclusive chemotherapy and to study the influence of nutritional status on their quality of life (QoL).

Methods

This work was a longitudinal cohort study performed at a French university teaching hospital. Eligible patients were individuals with a cancer needing treatment based on exclusive chemotherapy. Three work-ups were performed: i) before the administration of the first course of chemotherapy: T1, ii) before the administration of the second (for patients with 3 planned courses) or third (patients with 6 planned courses) course: T2, and iii) before the administration of the last planned course: T3. The following data were collected: general health (performance status) and nutritional status (weight, anorexia grading, albuminemia, pre-albuminemia, and C-reactive protein) and QoL.

Results

The nutritional status of patients with cancer was preserved. Functional impairment, the presence of anorexia, the palliative nature of the chemotherapy, and an elevated C-reactive protein dosage were independent predictive factors of a lower QoL among patients assessed at the end of chemotherapy.

Conclusions

Although larger studies should corroborate these findings, clinicians may include this information in the management of patients with cancer requiring exclusive chemotherapy to identify the most vulnerable patients.

Trial registration

Current controlled trials NCT01687335 (registration date: October 6, 2011).
Appendix
Available only for authorised users
Literature
1.
go back to reference Pressoir M, Desne S, Berchery D, Rossignol G, Poiree B, Meslier M, Traversier S, Vittot M, Simon M, Gekiere JP, et al. Prevalence, risk factors and clinical implications of malnutrition in French Comprehensive Cancer Centres. Br J Cancer. 2010;102:966–71.CrossRefPubMedPubMedCentral Pressoir M, Desne S, Berchery D, Rossignol G, Poiree B, Meslier M, Traversier S, Vittot M, Simon M, Gekiere JP, et al. Prevalence, risk factors and clinical implications of malnutrition in French Comprehensive Cancer Centres. Br J Cancer. 2010;102:966–71.CrossRefPubMedPubMedCentral
2.
go back to reference Hebuterne X, Lemarie E, Michallet M, de Montreuil CB, Schneider SM, Goldwasser F. Prevalence of malnutrition and current use of nutrition support in patients with cancer. JPEN J Parenter Enteral Nutr. 2014;38:196–204.CrossRefPubMed Hebuterne X, Lemarie E, Michallet M, de Montreuil CB, Schneider SM, Goldwasser F. Prevalence of malnutrition and current use of nutrition support in patients with cancer. JPEN J Parenter Enteral Nutr. 2014;38:196–204.CrossRefPubMed
3.
go back to reference Bosaeus I, Daneryd P, Lundholm K. Dietary intake, resting energy expenditure, weight loss and survival in cancer patients. J Nutr. 2002;132:3465S–6S.PubMed Bosaeus I, Daneryd P, Lundholm K. Dietary intake, resting energy expenditure, weight loss and survival in cancer patients. J Nutr. 2002;132:3465S–6S.PubMed
4.
go back to reference Salas S, Deville JL, Giorgi R, Pignon T, Bagarry D, Barrau K, Zanaret M, Giovanni A, Bourgeois A, Favre R, Duffaud F. Nutritional factors as predictors of response to radio-chemotherapy and survival in unresectable squamous head and neck carcinoma. Radiother Oncol. 2008;87:195–200.CrossRefPubMed Salas S, Deville JL, Giorgi R, Pignon T, Bagarry D, Barrau K, Zanaret M, Giovanni A, Bourgeois A, Favre R, Duffaud F. Nutritional factors as predictors of response to radio-chemotherapy and survival in unresectable squamous head and neck carcinoma. Radiother Oncol. 2008;87:195–200.CrossRefPubMed
5.
go back to reference Schutte K, Tippelt B, Schulz C, Rohl FW, Feneberg A, Seidensticker R, Arend J, Malfertheiner P. Malnutrition is a prognostic factor in patients with hepatocellular carcinoma (HCC). Clin Nutr. 2014;69:1290–1297. Schutte K, Tippelt B, Schulz C, Rohl FW, Feneberg A, Seidensticker R, Arend J, Malfertheiner P. Malnutrition is a prognostic factor in patients with hepatocellular carcinoma (HCC). Clin Nutr. 2014;69:1290–1297.
6.
go back to reference Illa P, Tomiskova M, Skrickova J. Nutritional risk screening predicts tumor response in lung cancer patients. J Am Coll Nutr. 2015;34:425–9.CrossRefPubMed Illa P, Tomiskova M, Skrickova J. Nutritional risk screening predicts tumor response in lung cancer patients. J Am Coll Nutr. 2015;34:425–9.CrossRefPubMed
7.
go back to reference Ravasco P, Monteiro-Grillo I, Camilo ME. Does nutrition influence quality of life in cancer patients undergoing radiotherapy? Radiother Oncol. 2003;67:213–20.CrossRefPubMed Ravasco P, Monteiro-Grillo I, Camilo ME. Does nutrition influence quality of life in cancer patients undergoing radiotherapy? Radiother Oncol. 2003;67:213–20.CrossRefPubMed
8.
go back to reference Salas S, Baumstarck-Barrau K, Alfonsi M, Digue L, Bagarry D, Feham N, Bensadoun RJ, Pignon T, Loundon A, Deville JL, et al. Impact of the prophylactic gastrostomy for unresectable squamous cell head and neck carcinomas treated with radio-chemotherapy on quality of life: Prospective randomized trial. Radiother Oncol. 2009;93:503–9.CrossRefPubMed Salas S, Baumstarck-Barrau K, Alfonsi M, Digue L, Bagarry D, Feham N, Bensadoun RJ, Pignon T, Loundon A, Deville JL, et al. Impact of the prophylactic gastrostomy for unresectable squamous cell head and neck carcinomas treated with radio-chemotherapy on quality of life: Prospective randomized trial. Radiother Oncol. 2009;93:503–9.CrossRefPubMed
9.
go back to reference Duguet A, Bachmann P, Lallemand Y, Blanc-Vincent MP: Bonnes pratiques diététiques en cancérologie: dénutrition et évaluation nutritionnelle. Bulletin du cancer. 1999;86:997–1016. Duguet A, Bachmann P, Lallemand Y, Blanc-Vincent MP: Bonnes pratiques diététiques en cancérologie: dénutrition et évaluation nutritionnelle. Bulletin du cancer. 1999;86:997–1016.
10.
go back to reference August DA, Huhmann MB. American Society for P, Enteral Nutrition Board of D: A.S.P.E.N. clinical guidelines: nutrition support therapy during adult anticancer treatment and in hematopoietic cell transplantation. JPEN J Parenter Enteral Nutr. 2009;33:472–500.CrossRefPubMed August DA, Huhmann MB. American Society for P, Enteral Nutrition Board of D: A.S.P.E.N. clinical guidelines: nutrition support therapy during adult anticancer treatment and in hematopoietic cell transplantation. JPEN J Parenter Enteral Nutr. 2009;33:472–500.CrossRefPubMed
11.
go back to reference Senesse P, Latino-Martel P. SFNEP oncology nutrition guidelines (Recommandations professionnelles de la Société Francophone Nutrition Clinique et Métabolisme). 2012. Senesse P, Latino-Martel P. SFNEP oncology nutrition guidelines (Recommandations professionnelles de la Société Francophone Nutrition Clinique et Métabolisme). 2012.
12.
go back to reference Bozzetti F, Arends J, Lundholm K, Micklewright A, Zurcher G, Muscaritoli M. Espen: ESPEN Guidelines on Parenteral Nutrition: non-surgical oncology. Clin Nutr. 2009;28:445–54.CrossRefPubMed Bozzetti F, Arends J, Lundholm K, Micklewright A, Zurcher G, Muscaritoli M. Espen: ESPEN Guidelines on Parenteral Nutrition: non-surgical oncology. Clin Nutr. 2009;28:445–54.CrossRefPubMed
13.
go back to reference Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC, et al. The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365–76.CrossRefPubMed Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC, et al. The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365–76.CrossRefPubMed
14.
go back to reference Ganz PA, Haskell CM, Figlin RA, La Soto N, Siau J. Estimating the quality of life in a clinical trial of patients with metastatic lung cancer using the Karnofsky performance status and the Functional Living Index--Cancer. Cancer. 1988;61:849–56.CrossRefPubMed Ganz PA, Haskell CM, Figlin RA, La Soto N, Siau J. Estimating the quality of life in a clinical trial of patients with metastatic lung cancer using the Karnofsky performance status and the Functional Living Index--Cancer. Cancer. 1988;61:849–56.CrossRefPubMed
15.
go back to reference Wallengren O, Lundholm K, Bosaeus I. Diagnostic criteria of cancer cachexia: relation to quality of life, exercise capacity and survival in unselected palliative care patients. Support Care Cancer. 2013;21:1569–77.CrossRefPubMed Wallengren O, Lundholm K, Bosaeus I. Diagnostic criteria of cancer cachexia: relation to quality of life, exercise capacity and survival in unselected palliative care patients. Support Care Cancer. 2013;21:1569–77.CrossRefPubMed
16.
go back to reference Garcia JM, Boccia RV, Graham CD, Yan Y, Duus EM, Allen S, Friend J. Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials. Lancet Oncol. 2015;16:108–16.CrossRefPubMed Garcia JM, Boccia RV, Graham CD, Yan Y, Duus EM, Allen S, Friend J. Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials. Lancet Oncol. 2015;16:108–16.CrossRefPubMed
17.
go back to reference Temel JS, Abernethy AP, Currow DC, Friend J, Duus EM, Yan Y, Fearon KC: Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials. Lancet Oncol. 2016;17:519–531. Temel JS, Abernethy AP, Currow DC, Friend J, Duus EM, Yan Y, Fearon KC: Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials. Lancet Oncol. 2016;17:519–531.
18.
go back to reference Vongmany N, Bousquet JP. Les cancers en France en 2014. données CL ed. Boulogne-Billancourt: INCa; 2015. Vongmany N, Bousquet JP. Les cancers en France en 2014. données CL ed. Boulogne-Billancourt: INCa; 2015.
Metadata
Title
Nutritional status and quality of life of cancer patients needing exclusive chemotherapy: a longitudinal study
Authors
Sebastien Salas
Sophie Mercier
Benjamin Moheng
Sandrine Olivet
Marie-Eve Garcia
Sophie Hamon
Camille Sibertin-Blanc
Florence Duffaud
Pascal Auquier
Karine Baumstarck
Publication date
01-01-2017
Publisher
BioMed Central
Published in
Health and Quality of Life Outcomes / Issue 1/2017
Electronic ISSN: 1477-7525
DOI
https://doi.org/10.1186/s12955-017-0660-6

Other articles of this Issue 1/2017

Health and Quality of Life Outcomes 1/2017 Go to the issue